BRIEF published on 11/04/2025 at 11:35, 10 months 16 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 10 months 16 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 1 year ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 1 year 1 month ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 1 year 1 month ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
PRESS RELEASE published on 07/25/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
BRIEF published on 07/21/2025 at 20:57, 1 year 1 month ago Advicenne raises 2.6 million euros to strengthen its financial capacity Capital Increase Financial Market Bpifrance Kidney Diseases Advicenna
BRIEF published on 03/27/2025 at 19:17, 1 year 5 months ago Advicenne Reports Solid Growth and Future Plans for 2025 Cash Flow Improvement 2025 Outlook Advicenne Financial Results Sibnayal Sales Growth ADV7103 Regulatory Progress
PRESS RELEASE published on 03/27/2025 at 19:12, 1 year 5 months ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
Published on 09/19/2026 at 00:55, 1 day 23 hours ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 22:00, 2 days 2 hours ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 2 days 4 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 2 days 10 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/20/2026 at 15:10, 9 hours 42 minutes ago MSITEK Participates in New York Fashion Week Retail Innovation Lab
Published on 09/20/2026 at 09:05, 15 hours 47 minutes ago Huawei Digital Power Showcases Multi-Scenario Solutions Featuring Grid Forming and AI at IDEE 2026
Published on 09/20/2026 at 06:30, 18 hours 22 minutes ago Huawei Grid-Interactive AIDC Solution: Shaping the New Paradigm of AI Infrastructure
Published on 09/20/2026 at 04:35, 20 hours 17 minutes ago How to Achieve Sustainable Power Without Changing Your Existing Backup System
Published on 09/19/2026 at 16:40, 1 day 8 hours ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/18/2026 at 18:34, 2 days 6 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 3 days 7 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
